SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76755.05
715.06 (-0.92%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,70,786 Large Cap	1,942.95 (-0.98%)	41.01	5.63	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Divis Laboratories Ltd.	Q V+ PT	1,94,590 Large Cap	7,386.75 (0.77%)	75.77	11.61	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,91,658 Large Cap	5,035.40 (-0.07%)	88.59	22.79	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,28,265 Large Cap	8,938.10 (0.20%)	85.93	12.87	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Cipla Ltd.	Q V PT	1,15,728 Large Cap	1,415.10 (-1.22%)	29.83	3.37	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Lupin Ltd.	Q V PT	1,14,967 Mid Cap	2,405.80 (-4.32%)	21.56	5.14	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Zydus Lifesciences Ltd.	Q V PT	1,14,080 Mid Cap	1,129.75 (-1.22%)	22.63	4.39	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Max Healthcare Institute Ltd.	Q V PT	1,07,094 Mid Cap	1,081.65 (-1.70%)	74.25	10.1	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Mankind Pharma Ltd.	Q V PT	1,06,460 Mid Cap	2,544.05 (-1.31%)	52.25	6.51	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Dr. Reddys Laboratories Ltd.	Q V+ PT	1,00,708 Mid Cap	1,183 (-1.95%)	24	2.67	12.09	15.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Aurobindo Pharma Ltd.	Q V+ PT	90,936 Mid Cap	1,532.95 (-3.01%)	37.66	4	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Laurus Labs Ltd.	Q V+ PT	86,059 Mid Cap	1,577.65 (-0.96%)	96.83	16.31	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Fortis Healthcare Ltd.	Q V+ PT	73,174 Mid Cap	949.55 (-2.03%)	317.68	7.93	23.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Biocon Ltd.	Q V PT	71,780 Mid Cap	437.95 (-0.57%)	1929.57	2.66	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Aster DM Quality Care Ltd.	Q V+ PT	70,967 Mid Cap	799.35 (-1.82%)	182.84	14.4	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Alkem Laboratories Ltd.	Q V+ PT	67,940 Mid Cap	5,588.75 (-1.65%)	31.09	4.85	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Glenmark Pharmaceuticals Ltd.	Q V+ PT	63,267 Mid Cap	2,198.20 (-1.95%)	46.46	6.02	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Abbott India Ltd.	Q V PT	61,146 Mid Cap	28,898.60 (0.43%)	39.4	12.88	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Ipca Laboratories Ltd.	Q V+ PT	45,636 Mid Cap	1,787.65 (-0.62%)	40.3	5.72	7.35	1.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Ajanta Pharma Ltd.	Q V+ PT	44,698 Mid Cap	3,459.25 (-3.31%)	42.33	9.88	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Anthem Biosciences Ltd.	Q V PT	44,603 Mid Cap	778.35 (-1.69%)	71.45	14.15	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	42,441 Mid Cap	2,551.10 (1.83%)	40.97	18.59	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Gland Pharma Ltd.	Q V PT	40,982 Small Cap	2,440.25 (-1.78%)	31.54	3.79	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Narayana Hrudayalaya Ltd.	Q V PT	40,826 Mid Cap	1,967.80 (-1.50%)	50.68	9	11.88	45.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Emcure Pharmaceuticals Ltd.	Q V PT	36,464 Small Cap	1,890.95 (-1.64%)	49.75	9.83	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Global Health Ltd.	Q V PT	36,050 Small Cap	1,353.75 (0.97%)	72.65	8.96	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Krishna Institute of Medical Sciences Ltd	Q V PT	33,206 Small Cap	784.15 (-0.82%)	127.37	8.45	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Wockhardt Ltd.	Q V+ PT	30,774 Small Cap	1,861.40 (-1.72%)	144.48	6.25	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Acutaas Chemicals Ltd.	Q V+ PT	30,088 Small Cap	3,667.50 (-0.21%)	82.17	18.03	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Dr. Lal Pathlabs Ltd.	Q V PT	28,511 Small Cap	1,699.65 (-0.06%)	56.1	11.85	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Nephrocare Health	673.50	7.74%
Park Medi World	281.70	3.97%
Shree Ganesh Remed.	658	3.49%
GPT Healthcare	155.15	2.68%
Sigachi Industries	26.46	1.97%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Bajaj Healthcare	323.05	-12.70%
Unichem Laboratories	527.80	-9.92%
Marksans Pharma	240.90	-7.47%
Panacea Biotec	461.90	-6.60%
Suven Life Sciences	319.15	-6.34%

News about Top Pharma Companies in India

Jul, 2026

Pharma stocks trade lower as Trump proposes steep tariff on generic drugs

Lupin is currently trading at Rs. 2422.75, down by 91.65 points or 3.65% from its previous closing of Rs. 2514.40 on the BSE

Jul, 2026

Anthem Biosciences - Quaterly Results

The sales declined to Rs. 3838.42 millions for the June 2026 quarter as compared to Rs. 5380.11 millions during the corresponding quarter last year.Net profit of the cmpany stood at Rs. 1020.10 millions for the quarter ended June 2026 a decline of -31.23% from Rs. 1483.41 millions in the same quarter last year.The company reported a degrowth in operating Profit to 1594.33 millions from 2231.57 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3838.42	5380.11	-28.66	3838.42	5380.11	-28.66	20893.12	18406.49	13.51
Other Income	286.00	277.28	3.14	286.00	277.28	3.14	1820.75	1094.40	66.37
PBIDT	1594.33	2231.57	-28.56	1594.33	2231.57	-28.56	10331.96	7984.49	29.40
Interest	7.63	16.06	-52.49	7.63	16.06	-52.49	65.47	90.89	-27.97
PBDT	1586.70	2215.51	-28.38	1586.70	2215.51	-28.38	10026.36	7893.60	27.02
Depreciation	223.10	226.12	-1.34	223.10	226.12	-1.34	995.65	779.37	27.75
PBT	1363.60	1989.39	-31.46	1363.60	1989.39	-31.46	9030.71	7114.23	26.94
TAX	343.50	505.98	-32.11	343.50	505.98	-32.11	2325.06	2052.36	13.29
Deferred Tax	-3.55	5.29	-167.11	-3.55	5.29	-167.11	-87.99	232.08	-137.91
PAT	1020.10	1483.41	-31.23	1020.10	1483.41	-31.23	6705.65	5061.87	32.47
Equity	1126.77	1123.22	0.32	1126.77	1123.22	0.32	1123.43	1118.15	0.47
PBIDTM(%)	41.54	41.48	0.14	41.54	41.48	0.14	49.45	43.38	14.00

Jul, 2026

Aurobindo Pharma’s arm gets ANVISA’s nod for biosimilars manufacturing facility in Hyderabad

The approval strengthens the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets

Jul, 2026

Emcure soars on getting nod to market Poviztra for treatment of non-cirrhotic MASH

The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease

Jul, 2026

Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH

The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease

Jul, 2026

GlaxoSmithKline Pharmaceuticals informs about board meeting

Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,70,786 Crore
2	Divis Laboratories Ltd.	1,94,590 Crore
3	Torrent Pharmaceuticals Ltd.	1,91,658 Crore
4	Apollo Hospitals Enterprise Ltd.	1,28,265 Crore
5	Cipla Ltd.	1,15,728 Crore
6	Lupin Ltd.	1,14,967 Crore
7	Zydus Lifesciences Ltd.	1,14,080 Crore
8	Max Healthcare Institute Ltd.	1,07,094 Crore
9	Mankind Pharma Ltd.	1,06,460 Crore
10	Dr. Reddys Laboratories Ltd.	1,00,708 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	28,899	61,146	39.40	12.88	27.01	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,035	1,91,658	88.59	22.79	45.98	29.04
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	21.56	5.14	12.47	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,459	44,698	42.33	9.88	28.59	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,589	67,940	31.09	4.85	22.55	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,578	86,059	92.06
Sai Life Sciences Ltd. (S)	Very Good	1,250	27,367	59.87
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,035	1,91,658	42.97
Aurobindo Pharma Ltd. (M)	Very Good	1,533	90,936	38.82
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	30.85
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,250	27,367	80.14	10.91	42.14	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,459	44,698	42.33	9.88	28.59	13.54
Mankind Pharma Ltd. (M)	Very Good	2,544	1,06,460	52.25	6.51	32.71	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,130	1,14,080	22.63	4.39	13.85	13.52
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	21.56	5.14	12.47	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	21.56	5.14	12.47	32.37
Abbott India Ltd. (M)	Very Good	28,899	61,146	39.40	12.88	27.01	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,183	1,00,708	24.00	2.67	13.45	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,130	1,14,080	22.63	4.39	13.85	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,943	4,70,786	41.01	5.63	23.51	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Pharma stocks trade lower as Trump proposes steep tariff on generic drugs

Anthem Biosciences - Quaterly Results

Aurobindo Pharma’s arm gets ANVISA’s nod for biosimilars manufacturing facility in Hyderabad

Emcure soars on getting nod to market Poviztra for treatment of non-cirrhotic MASH

Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH

GlaxoSmithKline Pharmaceuticals informs about board meeting

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.